Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02569723 · ClinicalTrials.gov registry record · NA
Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy
A NA study, sponsored by Edward Kim.
- Completed
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT02569723: Completed NA study, sponsored by Edward Kim.
NCT02569723 is a NA study that has completed, run by Edward Kim. The registered enrollment target is 6 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02569723, a NA study, has completed, sponsored by Edward Kim.
- COMPLETED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
This pilot clinical trial studies how well carbon C 14 oxaliplatin microdosing assay works in predicting exposure and sensitivity to oxaliplatin-based chemotherapy in patients with colorectal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Carbon C 14 is a radioactive form of carbon, exists in nature and in the body at a low level. Microdose carbon C 14 oxaliplatin diagnostic assay may help doctors understand how well patients respond to treatment and develop individualize oxaliplatin dosing in patients with colorectal cancer.
Primary Outcome
Correlate area under curve from phase 0 microdosing with area under curve for therapeutic dose of oxaliplatin
Interventions
- DRUG Oxaliplatin
- DRUG Carbon C 14 Oxaliplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-10-16 |
| Est. Completion | 2020-04-04 |
| Phase | NA |
What the finished NCT02569723 record still lists
NCT02569723 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Oxaliplatin is the first listed.
NCT02569723 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02569723 about?
NCT02569723 is a clinical study titled "Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy". This pilot clinical trial studies how well carbon C 14 oxaliplatin microdosing assay works in predicting exposure and sensitivity to oxaliplatin-based chemotherapy in patients with colorectal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment....
What is the current status of trial NCT02569723?
This trial is currently completed. It is a NA study. The enrollment target is 6 participants. The study started on 2015-10-16. Estimated completion is 2020-04-04.
What interventions are being tested in trial NCT02569723?
The interventions under investigation include: Oxaliplatin (DRUG), Carbon C 14 Oxaliplatin (DRUG).
Who is sponsoring clinical trial NCT02569723?
This trial is sponsored by Edward Kim, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02569723's enrollment target sits among peer trials
6 1983rd of 2000 higher than 13 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI